GlassScriptPhysician profile
Okan Elidemir
NPI 1073693313
$3,121.30
in general payments reported to CMS, 2019-2025
24 companies · $512 in 2025
The $512 reported for 2025 was more than what 78% of Pediatric Pulmonology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $398 · 2020: $362 · 2021: $675 · 2022: $365 · 2023: $388 · 2024: $422 · 2025: $512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,322.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $413.63 | 2019-2025 | Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $373.67 | 2019-2025 | Nucala |
| Electromed, INC. | $357.63 | 2019-2025 | Smartvest |
| Regeneron Healthcare Solutions, INC. | $268.36 | 2019-2025 | Dupixent |
| Baxter Healthcare | $264.61 | 2024-2025 | Coseal, Hillrom - Vest System Model 105 Home Care, Hillrom - Monarch Airway Clearance System |
| Abbvie INC. | $263.75 | 2019-2024 | |
| Chiesi USA, INC. | $201.69 | 2019-2021 | |
| Genentech USA, INC. | $178.97 | 2021-2024 | Xolair |
| Nestle Healthcare Nutrition INC. | $147.79 | 2021-2023 | |
| Advanced Respiratory, INC | $118.95 | 2021 | |
| Philips North America LLC | $100.74 | 2020-2024 | (Ak6) Vest Therapy |
| Genzyme Corporation | $75.59 | 2020-2023 | |
| Mylan Specialty L.P. | $64.18 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $56.48 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $50.73 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $40.97 | 2019 | |
| Alcresta Therapeutics, INC. | $40.90 | 2023-2024 | Relizorb |
| Vivus LLC | $38.51 | 2021-2023 | Pancreaze |
| Insmed, INC. | $21.51 | 2019 | |
| Gilead Sciences, INC. | $15.19 | 2021 | |
| Amgen INC. | $15.03 | 2025 | Tezspire |
| Pari Respiratory Equipment, INC. | $12.42 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Okan Elidemir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.